CYP3A43 Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP7999a
Background:
CYP3A43 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein has a low level of testosterone hydroxylase activity. Although it bears homology to some drug-metabolizing cytochrome P450s, the protein unknown whether the enzyme is also involved in xenobiotic metabolism.
Other Names:
Cytochrome P450 3A43, CYP3A43
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7999a was selected from the N-term region of human CYP3A43. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CYP3A43
Gene ID: 64816
Primary Accession: Q9HB55
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
CYP3A43 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein has a low level of testosterone hydroxylase activity. Although it bears homology to some drug-metabolizing cytochrome P450s, the protein unknown whether the enzyme is also involved in xenobiotic metabolism.
Other Names:
Cytochrome P450 3A43, CYP3A43
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP7999a was selected from the N-term region of human CYP3A43. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CYP3A43
Gene ID: 64816
Primary Accession: Q9HB55
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review